Trial Profile

A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemnifosbuvir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Proof of concept
Sponsors Atea Pharmaceuticals

Most Recent Events

15 Nov 2024 According to an Atea Pharmaceuticals, Inc. media release, data from this trial presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024.
15 Nov 2024 Results presented in an Atea pharmaceuticals media release.
30 Sep 2019 Results published in the Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com